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AbstrAct:
Squamous cell cancer of the head and neck (SCCHN) is the sixth leading cause for 
cancer deaths worldwide. Despite extense knowledge of risk factors and pathogenesis 
about 50 percent of all patients and essentially every patient with metastatic SCCHN 
eventually die from this disease. We analyzed the clinical data and performed 
immunohistochemistry for Epidermal growth factor receptor (EGFR) and Aurora 
kinase A (Aurora-A) expression in 180 SCCHN patients. Patients characterized by 
elevated EGFR and elevated Aurora-A protein expression in tumor tissue represent 
a risk group with poor disease-free and overall survival (EGFRlowAurora-Alow versus 
EGFRhighAurora-Ahigh, p=0.024). Treating SCCHN cell lines with a pan-Aurora kinase 
inhibitor resulted in defective cytokinesis, polyploidy and apoptosis, which was 
effective irrespective of the EGFR status. Combined Aurora kinase and EGFR targeting 
using a monoclonal anti-EGFR antibody was more effective compared to single EGFR 
and Aurora kinase inhibition. Comparing pan-Aurora kinase and Aurora-A targeting 
hints towards a strong and clinically relevant biological effect mediated via Aurora 
kinase B (Aurora-B). Taken together, our findings characterize a new poor risk group 
in SCCHN patients defined by elevated EGFR and Aurora-A protein expression. Our 
results demonstrate that combined targeting of EGFR and Aurora kinases represents 
a therapeutic means to activate cell cycle checkpoints and apoptosis in SCCHN.
IntroductIon
Squamous cell cancer of the head and neck (SCCHN) 
is the sixth leading cause for cancer deaths worldwide [1]. 
Despite recent progress in understanding SCCHN biology 
and improved treatment, the 5 year survival has remained 
50 percent for the past two decades. There is a pressing 
need to improve therapy in particular for patients with 
metastatic disease or local recurrence, where the median 
progression-free and overall survival is only ~ 6 months 
and ~11 months, respectively [2-4]. 
Several genetic alterations have been described in 
SCCHN, including mutations in the p53 tumor suppressor 
gene and mutations in genes that encode cell cycle proteins 
such as p16 and cyclin D1. In addition, several oncogenic 
pathways including Ras, PI3K/PTEN/Akt, TGF-β/BMP 
and EGFR/STAT3 are up-regulated in SCCHN [4-11]. 
Epidermal growth factor receptor (EGFR) overexpression 
in SCCHN is often caused by gene amplification [12], and 
elevated expression correlates with poor disease control 
and metastasis [13-14]. Furthermore, overexpression of 
two of its ligands, EGF and transforming growth factor-
alpha (TGF-alpha), has been linked to a poor prognosis 
[15]. The major signaling pathways activated by EGFR 
are the RAS-RAF-MAP kinase pathway, which is mainly 
involved in proliferation, and the PI3K-PTEN-AKT 
pathway, which is mainly involved in survival [16]. The Oncotarget 2011; 2:  599 - 609 600 www.impactjournals.com/oncotarget
addition of the monoclonal antibody C225 (cetuximab) 
to the standard first-line regimen cisplatin/5-fluorouracil 
[17] not only increased the rate of objective responses but 
also improved progression-free and overall survival in 
patients with recurrent or metastatic SCCHN [2]. 
The  Aurora  kinases  A  and  B  (Aurora-A  and 
Aurora-B) are highly conserved serine/threonine kinases 
that play essential and distinct roles in mitosis [18]. 
Specifically, Aurora-A  is  required  for  the  assembly  of 
the mitotic spindle, where it accumulates on centrosomes 
at the spindle poles during prophase until metaphase. 
Recently a kinase-independent role in mitotic spindle 
assembly has been reported for Aurora-A [19]. Aurora-B 
is required for mitotic progression and cytokinesis, and is 
localized, along with inner centromeric protein (INCENP) 
and survivin, at centromeres and the spindle midzone 
during the metaphase to anaphase transition [18, 20]. 
AURORA-A (AURKA) mRNA is amplified in a variety of 
human cancers including SCCHN, where it is associated 
with poor prognosis [21]. Increased levels of Aurora-B 
have been reported in various aggressive malignancies 
[20].
Both  Aurora-A  and  EGFR  overexpression  have 
been implicated in SCCHN tumorigenesis and are 
established adverse prognostic factors. Aurora-A and 
EGFR share downstream signaling pathways, and each 
by itself represents an attractive therapeutic target. Here 
we report that joint protein overexpression of EGFR 
and Aurora-A defines a poor risk group among SCCHN 
patients. Combining drugs that target Aurora kinases and 
Figure 1: EGFR and Aurora-A transcript levels in 
sccHN and clinical outcome. A public database (www.
oncomine.com) was searched for gene expression analyses 
studies that compare AURORA-A transcript levels in control 
tissue and SCCHN samples from patients who were alive or dead 
[22]. Shown is the log2 median-centered relative intensity of 
expression for AURORA-A (AURKA, upper panel, tumor versus 
control tissue: p= 0.002, [reporter: 34851_at]) and EGFR (lower 
panel, tumor versus control tissue: n.s., [reporter: 1537_at]).
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Figure 2: EGFr and Aurora-A expression in tumor tissue and adjacent normal mucosa. (A) Histological assessment of 
EGFR and Aurora-A protein expression by immunohistochemistry. Shown are representative tumor samples that were graded as negative/
low expression (middle panel), high expression (lower panel) and normal mucosa control tissue (upper panel). Bar equals 100µm. (B) 
Within each patient sample the expression of Aurora-A and EGFR was assessed in normal adjacent tissue and tumor tissue. The differences 
are highly significant. Aurora-A: p<0.001; EGFR: p<0.001. The staining score is defined in the material and method section.
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EGFR may overcome resistance to single agent treatment 
in SCCHN cells. 
rEsults
High levels of EGFr and Aurora-A assessed by 
IHc identify adverse prognosis in sccHN 
Publicly available gene expression data [22] 
(www.oncomine.org) were analyzed for the expression 
and prognostic relevance of EGFR and AURORA-A 
expression. AURORA-A transcripts were expressed at 
significantly higher levels in SCCHN tumor samples as 
compared to normal control tissue (p=0.002, Figure 1), and 
the median relative expression in surviving patients was 
lower as compared to patients dying from SCCHN (n.s.). 
In a previous report the level of AURORA-A transcript was 
associated with survival [21]. We therefore next addressed 
the prognostic relevance of Aurora-A and EGFR protein 
levels in the SCCHN patient cohort (n=180) described in 
Table 1. There was a highly significant difference between 
patients’ protein levels when comparing normal adjacent 
mucosa with the levels expressed in tumor cells for both 
Aurora-A and EGFR (Figure 2A), with independent 
expression of EGFR and Aurora-A for each patient (r=0.03 
/ p=0.74). Furthermore, there were clear differences in 
expression levels for Aurora-A and EGFR within the 
patient tumor tissue assessed (Figure 2). While protein 
levels  of  EGFR  (Figure  3A)  or Aurora-A  (Figure  3B) 
above median assessed by IHC in a Kaplan Meier analysis 
did not identify a population with a significantly reduced 
disease-free survival (EGFR: p=0.10; Aurora-A; p=0.21), 
our analysis identifies a poor risk population with regard 
to overall and disease-free survival that is characterized 
by above median levels of EGFR (EGFRhigh) and 
Aurora-A (Aurora-Ahigh) (p=0.024, compared to EGFRlow 
and Aurora-Alow, Figure 2C). Thus, the coexpression 
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Figure 3: EGFr and Aurora-A expression assessed by 
IHc is an adverse prognostic factor in sccHN. (A) 
EGFR: the difference in disease-free survival for patients with 
expression above median (green curve; n=90) is not statistically 
different from the survival of patients with expression below 
median (blue curve; n=90). p=0.10. (B) Aurora-A: the difference 
in disease-free survival for patients with expression below 
median (blue curve; n=90) is not statistically different from the 
survival of patients with expression above median (green curve; 
n=90). p=0.21. (C) The difference in disease-free survival of 
patients with EGFRhigh and Aurora-Ahigh is statistically different 
from the survival of patients who are characterized by EGFRlow 
and Aurora-Alow. p=0.024. The staining score is defined in the 
material and method section.
table 1: Patient characteristics (n=180).
characteristic number (%)
sex female 17 (9)
male 163 (91)
localisation oral cavity 33 (18)
oropharynx 58 (32)
hypopharynx 33 (18)
larynx 56 (31)
primary tumor category (pt) pT1 25 (14)
pT2 66 (37)
pT3 48 (27)
pT4 41 (23)
lymph node category (c/pn) c/pnN0 94/52
pN1 23 (13)
pN2a 2 (1)
pN2b 39 (22)
pN2c 20 (11)
pN3 2 (1)
tumor grade G1 10 (6)
G2 110 (61)
G3 60 (33)Oncotarget 2011; 2:  599 - 609 602 www.impactjournals.com/oncotarget
of elevated levels of Aurora-A and EGFR is an adverse 
prognostic factor in SCCHN. 
Aurora kinase inhibition results in defective 
cytokinesis and polyploidy irrespective of the 
EGFr status
Given our results (Figure 3) and mRNA data showing 
that Aurora-A expression is an adverse prognostic factor 
[21], molecular targeted therapy towards Aurora kinases 
could be an attractive approach. We first characterized six 
SCCHN cell lines for the expression of EGFR, Aurora-A 
and Aurora-B. As expected all cell lines showed detectable 
levels of Aurora kinases as well as phosphorylation of 
the Aurora kinase substrate Serin10-phosphorylated 
Histone H3 (S10-HH3) [23](Figure 4A). Real-time PCR 
analysis revealed no clear correlation between transcript 
and  protein  level  for  Aurora-A  or  Aurora-B  (Figure 
4B, upper panel). We next assessed the presence of the 
EGFR variant III (EGFRvIII), which has been reported 
to contribute to tumor growth and resistance to EGFR 
A B
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Figure 4: Expression and activity of Aurora kinases and EGFr in sccHN cell lines. (A) Six SCCHN cell lines were assessed 
by immunoblotting for the expression of Aurora-A and Aurora-B, for Aurora kinase activity measured by Histone H3 phosphorylation at 
serine10 (S10-HH3), and for EGFR protein levels. (B) Upper panel: AURORA-A and AURORA-B transcript levels were assessed by real-
time qRT-PCR. Shown is the relative expression normalized to the expression of Ubiquitin. Lower panel: Expression of EGFR analyzed 
by RT-PCR. None of the SCCHN cell lines express the EGFRvIII mutant. Transiently transfected NIH-3T3 cells expressing EGFRvIII 
(3T3-EGFRvIII) were included as a control. (C) Upper panel: CAL cells were treated with 200 nM Cetuximab for the indicated time and 
assessed by immunoblotting for suppression of EGFR downstream target phosphorylation. Lower panel: Treatment of FADU cells with 
5 nM Pan-Aurora kinase inhibitor R763 for the indicated time. The activity of Aurora kinases was assessed by immunoblotting for S10-
HH3. (D) SCCHN cell lines were treated for 24 hr with R763 at the indicated concentrations or carrier alone (0 nM). The representative 
histograms show the DNA content assessed by propidium iodide (PI) staining.Oncotarget 2011; 2:  599 - 609 603 www.impactjournals.com/oncotarget
targeting [24]. EGFRvIII was not present in any of the 
cell lines analyzed by RT-PCR, where NIH-3T3 cells that 
were engineered to ectopically express EGFRvIII were 
included as a control (Figure 4B, lower panel). We next 
analyzed the effects of the EGFR antibody cetuximab 
and the small molecule pan-Aurora kinase inhibitor R763 
[25] on SCCHN cells. Treatment with 200 nM cetuximab 
resulted in reduced autophosphorylation of EGFR after 
5 minutes, which subsequently resumed to normal and 
above normal levels consistent with a previous report 
[26]. In accord, the abundance of phosphorylated Akt and 
Erk upon cetuximab treatment was reduced [27] (Figure 
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Figure 5: Combined exposure to EGFR antibody and Aurora kinase inhibitor results in fortified growth inhibition 
and apoptosis. (A) SCCHN cells were treated for a total of 14 days with cetuximab (200 nM), the Aurora kinase inhibitor R763, the 
combination of both (Cet+ R763), or carrier only (control). The cell number was counted at the indicated times and the -fold increase in 
cell number calculated. Note that the increase in cell number is given in a logarythmic scale. The combination of cetuximab and Aurora 
kinase inhibitor resulted in a significantly reduced -fold increase after 14 day treatment period in all cell lines investigated in comparison 
to all other conditions (Cet alone, R763 alone, control; p<0.05). (B) The indicated SCCHN cells were cultured for a 48 hr period with the 
indicated conditions (cetuximab 200 nM, R7635 nM) and assessed for DNA content by PI staining. The percentage of polyploid cells with 
a DNA content >4n is given. (C) Analysis of the cells shown in (B) for apoptosis (Annexin V-positive, PI-negative cell fraction) by flow 
cytometry. The bars represent the mean ± SD of 3 independently performed experiments. Statistically significant differences are marked 
(* indicates p<0.05). Oncotarget 2011; 2:  599 - 609 604 www.impactjournals.com/oncotarget
4C, upper panel). We then assessed the abundance of S10-
HH3 as a measure of Aurora kinase activity. The exposure 
to 5 nM R763 lead to a rapid and efficient decrease in S10-
HH3 levels (Figure 4C, lower panel). In order to assess the 
Aurora kinase inhibition effects on ploidy and cell death 
we next treated SCCHN cell lines for a 24 hour period 
with R763 at various concentrations. There was a strong 
effect with regard to G2-M arrest and/or ploidy (p<0.05 
in all cell lines, Figure 4D) and to a lesser extent to the 
subG1 fraction of SCCHN cells, indicating that mitosis 
and cytokinesis were effectively blocked. R763 treatment 
did however result in low apoptosis rates. In conclusion, 
a low nanomolar concentration of the Aurora kinase 
inhibitor R763 resulted in effective inhibition of Aurora 
kinase activity, of cytokinesis and caused polyploidy.
Additive effects of combined Aurora kinase and 
EGFr targeting 
Given that we found Aurora-A and EGFR protein 
expression as adverse prognostic factor in SCCHN, 
Figure 6
A
E
%
 
p
o
l
y
p
l
o
i
d
 
c
e
l
l
s
0
4
8
B
0 5 10 15 20
0.1
1
10
100
1000
10000
100000 ctrl
Cet+Mln
days
D
ctrl
Cet+R763
Cet+Mln 0
5
10
15
20
25
%
 
p
o
l
y
p
l
o
i
d
 
c
e
l
l
s
%
 
a
p
o
p
t
o
t
i
c
 
c
e
l
l
s
ctrl
Cet+R763
Cet+Mln 0
2
4
6
ctrl
Cet+R763
Cet+Mln 0
20
40
60
80
ctrl
Cet+R763
Cet+Mln 0
20
40
60
80
ctrl
Cet+R763
Cet+Mln 0
1
2
3
ctrl
Cet+R763
Cet+Mln 0
5
10
15
ctrl
Cet+R763
Cet+Mln 0
2
4
6
8
10
ctrl
Cet+R763
Cet+Mln 0
2
4
6
8
ctrl
Cet+R763
Cet+Mln 0
5
10
15
20
ctrl
Cet+R763
Cet+Mln 0
5
10
15
20
ctrl
Cet+R763
Cet+Mln 0
5
10
15
20
25
ctrl
Cet+R763
Cet+Mln 0
2
4
6
8
BHY CAL HN FaDu SAS XF354
BHY CAL HN FaDu SAS XF354
S10-HH3
Actin
minutes
-
f
o
l
d
 
i
n
c
r
e
a
s
e
(
c
e
l
l
 
n
u
m
b
e
r
) c
Figure 6: Selective Aurora-A inhibition versus pan-Aurora kinase inhibition in combination with Cetuximab. (A) 
FADU cell were treated with 10 nM Mln for the indicated time. The effect of Aurora-A inhibition was assessed by immunoblotting for 
serine10-phosphorylated Histone H3 (S10-HH3). (B) Mln treatment (10 nM) for 48 hr resulted in a significant (p<0.05) but moderate 
increase of polyploid cells (>4n DNA content) as evaluated by PI flow cytometry. (C) Combined Aurora-A inhibiton with 10 nM Mln and 
EGFR inhibition with 200 nM cetuximab treatment results a significantly reduced cell number increase. (D) The indicated SCCHN cell 
lines were treated for 48 hr with carrier only or cetuximab plus R763 (Cet+ R763) or cetuximab plus Mln (Cet+Mln). The percentage of 
polyploid cells as defined by a DNA content >4n was measured by flow cytometry of PI stained cells. (E) Cells were treated as in (C). The 
percentage of apoptotic cells was assessed by Annexin V flow cytometry. The bars represent the mean ± SD of 3 independent experiments. 
The differences between Cet+ R763 versus Cet+Mln treatment are significant (p<0.05) for all cell lines tested with regard to polyploidy 
and with regard to apoptosis. Oncotarget 2011; 2:  599 - 609 605 www.impactjournals.com/oncotarget
targeting both is an attractive therapeutic approach. We 
therefore assessed whether combined targeting using 
R763 and cetuximab would result in increased cell cycle 
effects and/or apoptosis. To mimic the in vivo drug action 
we estimated the long term effects of EGFR and/or Aurora 
kinase targeting in asynchronously growing SCCHN 
cultures. SCCHN growth curves revealed that the addition 
of 200 nM cetuximab or 5 nM R763 results in a delayed 
growth inhibition starting at around 7 days after treatment 
initiation (data not shown). The effects of a combination 
treatment in longer term cell culture were significantly 
pronounced (Figure 5A). Quite surprisingly, in cell lines 
that showed no or very moderate growth inhibition upon 
cetuximab  only  treatment  (BHY  and  FaDu),  addition 
of the Aurora kinase inhibitor led to an additive growth 
inhibition (Figure 4A), even in cells that are characterized 
by very low EGFR expression (BHY, Figure 4A). Thus, 
the combination of Aurora kinase inhibition and EGFR 
targeting is highly efficient in vitro and may overcome 
cetuximab resistance.
To mechanistically address the additive effect 
SCCHN cells were incubated with 5 nM R763, which 
blocked kinase activity effectively (Figure 4C), 200 
nM  cetuximab  or  the  combination  of  both  drugs,  and 
compared to untreated controls. 48 hour treatment 
with  cetuximab  showed  minor  efficacy  with  regard  to 
cell cycle arrest and polyploidy or apoptosis induction 
assessed by PI staining or AnnexinV positivity. 48 hour 
treatment with R763 resulted in a significant increase in 
polyploid (Figure 5A) and apoptotic cells (Figure 5B). 
The combination of cetuximab and R763 did not lead to 
a significantly increased fraction of cells with a polyploid 
phenotype representing defective mitosis and cytokinesis 
as compared to R763 monotherapy (Figure 5A), but, 
importantly, in several cell lines to a significantly elevated 
percentage of cell death (subG1 DNA content, data not 
shown), and AnnexinV positive apoptotic cells (Figure 
5B). Thus, combined EGFR and Aurora kinase targeting 
results in additive effects, potentially by sensitizing 
mitotic checkpoints.
selective Aurora-A inhibition is less effective than 
combined Aurora kinase inhibition
R763 is a pan-Aurora kinase inhibitor that inhibits 
Aurora-A and Aurora-B [28]. To further analyze whether 
Aurora-A, a prognostic factor in SCCHN [21](and this 
report Figure 3), or Aurora-B is the major target of R763 
in SCCHN, we next directly compared R763 with the 
Aurora-A  specific  kinase  inhibitor  MLN8237  (Mln). 
Mln  effectively  blocked  S10-HH3  phosphorylation  at 
10nM (Figure 6A). Mln treatment furthermore resulted 
in an increase of the fraction of polyploid cells (Figure 
6B), and combined EGFR and Aurora-A targeting using 
Mln decreased the growth of SCCHN cells significantly 
(Figure 6C). A direct comparison of the Pan-Aurora 
kinase inhibitor R763 (5nM) and the Aurora-A specific 
kinase inhibitor Mln (10nM) at concentrations that each 
block S10-HH3 phosphorylation effectively revealed that 
the R763/cetuximab combination was much more potent 
in inducing polyploidy (Figure 6D) as well as apoptosis 
(Figure 6E) compared to cetuximab in combination with 
the specific Aurora-A inhibitor Mln. Thus, the superior 
effects of R763 are most likely mediated by its blockage 
of Aurora-B activity or its dual Aurora kinase inhibition.
DIscussIoN
Other than EGFR blockage through cetuximab, 
none of the targeted approaches have yet shown clinically 
convincing results or changed the standard of care in 
relapsed or metastatic SCCHN. We identify the Aurora 
kinases as potential targets in this disease. Aurora kinases 
are upregulated in multiple human cancers, correlating 
in some cases with poor prognosis [18, 20-21, 29]. By 
investigating 180 patient samples of SCCHN tumors we 
show  that  both  Aurora-A  and  EGFR  are  significantly 
overexpressed in tumor tissue. The spearman correlation 
coefficient showed that the expression of Aurora-A and 
EGFR was independent. Our findings thus establish that 
the joint overexpression of EGFR and Aurora-A defines 
a subgroup of SCCHN patients with inferior prognosis 
regarding disease-free and overall survival. These results 
prompt the analysis of combined targeted treatment 
strategies in this disease. We used a dual Aurora-A/
Aurora-B inhibitor in combination with EGFR blockage 
through cetuximab and established an additive or possibly 
even synergistic effect on SCCHN cells in vitro. At 
this time it is however not clear whether Aurora-B was 
the main therapeutic target in our SCCHN studies or 
whether combined inhibition of Aurora-A and Aurora-B 
is beneficial. In a targeted small interfering RNA screen 
others identified Aurora-A as a component of an EGFR-
centered network. When the Aurora kinase inhibitor PHA-
680632 (PHA) was combined with EGFR inhibition, 
therapeutic synergism was observed in EGFR-dependent 
cell lines [30]. It has however to be noted that the applied 
concentrations of PHA most likely also inhibit Aurora-B 
[31]. There is further linkage between EGFR activation 
and Aurora-A. A study demonstrated that the nuclear 
EGFR can cooperate with STAT5A to target the promoter 
region of AURORA-A and enhance its expression in 
cancer cells [32]. 
A  consistent  finding  in  our  in  vitro  study  is  that 
there is a uniform additive inhibition of cell growth when 
cetuximab and Aurora kinase inhibition was combined, 
even in cell lines that were resistant towards EGFR-directed 
treatment or that showed moderate growth inhibition upon 
single Aurora kinase targeting. Our immunohistochemical 
studies did not address the frequency of the EGFRvIII 
mutant that might be associated with resistance towards Oncotarget 2011; 2:  599 - 609 606 www.impactjournals.com/oncotarget
cetuximab [24]. The cell lines we used did not express 
EGFRvIII. At this time we cannot conclude whether 
EGFRvIII bearing SCCHN patients have an inferior 
prognosis (our retrospective cohort) or whether EGFRvIII 
mutant cell lines are different with regard to sensitivity 
towards Aurora kinase inhibition. A recent clinical trial 
indicated that high EGFRvIII expression levels identify 
SCCHN  patients  who  are  less  likely  to  benefit  from 
combination treatment with cetuximab and docetaxel 
[33]. However, our studies suggest that even inhibiting a 
very low level of EGFR expression might be sufficient 
to sensitize for Aurora kinase inhibition. This could occur 
by either concertedly targeting the same growth and/or 
survival pathways or by blocking resistance-mediating 
mechanisms. 
The  G2-M  targeting  approach  is  of  particular 
interest since conventional chemotherapy usually targets 
cancer cells at the G1-S transition of the cell cycle. The 
cell cycle is driven by Cyclin-dependent kinases (Cdk). 
Of particular importance is the negative regulation of 
Cdk by checkpoints when defects such as DNA damage 
occur. Following DNA damage the transcription factor 
p53 is activated, which results in transcription of the Cdk 
inhibitor p21 and cell cycle arrest in G1, or induction of 
apoptosis [34]. Loss of p53 function, a frequent event in 
SCCHN [4, 35], therefore has the dual effect of loss of the 
G1-S checkpoint and loss of an important pathway leading 
to death [36]. On the other hand G2-M checkpoint genes 
are rarely if ever mutated in cancer. Therefore therapeutics 
targeting  cancer  cells  at  G2-M  and  during  cytokinesis 
are highly interesting. Current therapeutic strategies 
in SCCHN use mitotic poisons such as taxanes, which 
act directly on spindle microtubules inducing spindle 
assembly checkpoint (SAC) activation, and prolonged 
mitotic arrest that frequently ends in cell death [37]. A 
second approach is to directly target mitotic checkpoint 
kinases such as Aurora kinases. Several of the currently 
available Aurora kinase inhibitors target both Aurora-A 
and Aurora-B. Comparing the pan Aurora kinase inhibitor 
R763 [25] with the Aurora-A specific inhibitor MLN our 
results establish Aurora-B as the potentially more powerful 
target in SCCHN, but cannot rule out that a combined 
Aurora-A and Aurora-B inhibition might be beneficial to 
induce mitotic failure and cell death. Importantly, there are 
interactions between Aurora-A and p53, where Aurora-A 
directly phosphorylates p53 to augment p53 protein 
turnover and transcriptional activity [38]. In addition, a 
differential effect of Aurora kinase inhibition related to 
function p53 has been suggested [39]. 
The G2-M checkpoint is a particularly interesting 
therapeutic target in SCCHN, where due to the high 
frequency of mutations in the p53 apoptotic pathway the 
G1-S checkpoint is often dysfunctional. Our results define 
a new risk group in SCCHN and provide a rationale for 
testing combined EGFR and Aurora kinase targeting in 
clinical studies. 
MAtErIAls AND MEtHoDs
Patient selection and tissue samples
Paraffin  wax-embedded  tumor  samples  from  180 
patients (mean age 54 years, range 30-70 years) with a 
squamous cell carcinoma of the oral cavity, oropharynx, 
hypopharynx and larynx were investigated. Patients had 
been treated by radical surgical resection between 1993 
and 1997 in the Department of Head and Neck Surgery, 
Klinikum rechts der Isar, Technische Universität München 
(TUM), Munich, Germany or in the Department of Head 
and Neck Surgery, University of Regensburg, Regensburg, 
Germany.
The pT and pN categories of the tumor were 
determined according to the tumor-node-metastasis 
classification  [40]  and  tumor  grading  according  to 
the  World  Health  Organization  (WHO)  classification 
[41]. For all tumors and patients, histopathological and 
clinical follow-up data were available (mean follow-up 
period 6.6 years, follow-up period of 0.02 to 13.6 years). 
Clinical and histopathological data were correlated with 
expression patterns of Aurora-A and EGFR. The study 
was approved by the Ethics Committee of the Medical 
Faculty of the TUM. Detailed patient characteristics and 
histomorphological features are shown in Table 1.
Preparation of tissue MicroArrays (tMA), 
Immunohistochemistry (IHc), and scoring
For each of the 180 SCCHN, one paraffin block was 
selected. An experienced pathologist marked the viable, 
representative areas of tumor specimens. Core needle 
biopsy specimens were retrieved from the original tumor 
blocks by using a manual arrayer (Beecher Instruments, 
Sun  Prairie,  WI,  USA)  and  positioned  in  a  recipient 
paraffin wax array block. We aimed to obtain at least three 
tissue cylinders per tumor with a diameter of 0.6 mm from 
each biopsy specimen.
IHC was performed on deparaffinized tissue sections 
(2µm), stained with antibodies against Aurora kinase A 
(Novocastra,  Leica-Microsystems,  Wetzlar,  Germany) 
and  EGFR  (Santa  Cruz  Biotechnology,  Santa  Cruz, 
CA), visualized with peroxidase-conjugated secondary 
antibody  (LSAB  Kit,  DAKO,  Hamburg,  Germany). 
The  tissue  sections  were  counterstained  with  Mayer 
hematoxylin solution. For positive controls, we used 
tissues with known expression of the respective antigens. 
For negative controls, we used irrelevant antibodies with 
the same immunoglobulin isotype.
According to previously published criteria 
cytoplasmatic and/or nuclear immunoreactivity of 
Aurora-A [21] and the membrane and/or cytoplasmatic 
staining of EGFR [42] was evaluated in three tumor areas of Oncotarget 2011; 2:  599 - 609 607 www.impactjournals.com/oncotarget
each case. Immunoreactivity was scored into seven groups 
according to the percentage and intensity of cytoplasmic, 
nuclear and membrane staining of the positively stained 
tumor cells. Specimens with > 60% of cells stained were 
scored as strongly positive (4+), those with 30-60% of 
cells stained were scored as moderately positive (3+), 
those with 10-20% of cells stained were scored as weakly 
positive (2+), those with < 10% cells stained were scored 
as less weakly positive (1+). Specimens with no staining 
were scored as negative. The intensity of staining was 
grouped in strong (3+), moderate (2+) and weak (1+). 
Intensity and percentage of staining cells were added up 
identifying the seven groups. All scoring analysis was 
done by two independent investigators. To compare high 
with low expression levels, a median split analysis was 
applied. EGFR≥5 and Aurora-A≥5 were specified as high 
expression. 
cell culture, transfection and plasmids
All cell lines were obtained from ATCC-LGC 
(Wesel, Germany) or DSMZ (Braunschweig, Germany). 
SCCHN  cells  were  cultured  in  DMEM  (Invitrogen, 
Darmstadt, Germany) supplemented with 10% heat 
inactivated  fetal  bovine  serum  (FBS,  PAA,  Cölbe, 
Germany), 1% glutamine, 1% penicillin-streptomycin 
and 1% non-essential amino acids (all from Invitrogen, 
Darmstadt, Germany) . NIH-3T3 cells were cultured in 
DMEM supplemented with 10% heat inactivated bovine 
serum and 1% penicillin-streptomycin. NIH-3T3 cells 
were transfected with pLERN-EGFRvIII (kind gift of 
Frank Furnari, La Jolla, CA) with Lipofectamine 2000 
according to the manufacturer’s instructions (Invitrogen, 
Darmstadt, Germany) and selected with G418 (1000µg/
ml, Sigma, Munich, Germany). To measure proliferation, 
SCCHN cells were split, reseeded (5x105 in 25cm2 flasks), 
and counted at the indicated time points. Cells were then 
replated at the initial density. The -fold increase in cell 
number was calculated, all given results are based on 
triplicate experiments. R763 [25] was kindly provided by 
EMD-Serono (Rockland, MA). MLN8237 was purchased 
from Selleck (Houston, TX).
Flow cytometry and apoptosis assays
To assess apoptosis, 5x105 cells were stained with 
FITC-labeled Annexin V (BD Pharmingen, Heidelberg, 
Germany) and counterstained with propidium iodide 
(PI,  Sigma,  Munich,  Germany).  Following  incubation 
cells were washed, resuspended in PBS, and analyzed by 
flow cytometry. The fraction of Annexin V–positive (FL2 
channel) PI-negative (FL3 channel) cells was reported 
as apoptotic. For analysis of cell cycle distribution, cells 
were fixed with 70% ethanol and stained with PI. Flow 
cytometric analysis of DNA content was performed using 
PI in the FL2 channel in linear mode. Cells with less than 
diploid DNA content were considered dead (sub-G1), 
cells with more than 2N DNA content were considered 
polyploid.
rNA preparation and analyses
For reverse transcriptase quantitative PCR (qRT-
PCR), RNA was prepared from cultured cells using the 
RNeasy kit (Qiagen, Hilden, Germany). cDNA was 
prepared from 2µg RNA using the SuperScript II reverse 
transcriptase cDNA synthesis kit (Invitrogen, Darmstadt, 
Germany).  qRT-PCR  was  performed  on  an ABI  Prism 
7900 cycler (Applied Biosystems, Darmstadt, Germany) 
with  the  Platinum  SYBR  Green  qPCR  SuperMIX-
UDG kit (Invitrogen, Darmstadt, Germany). Data were 
analyzed by using the ∆Ct method, where Ubiquitin 
served as an internal control, with one sample set as 1. 
RT-PCR was performed to validate the expression of the 
EGFRvIII mutant in NIH-3T3 cells. Primer sequences can 
be obtained from the authors upon request.
Immunoblotting
Protein extracts (50µg per lane) were 
electrophoretically separated on SDS-PAGE gels, 
transferred to membranes (Protran, Schleicher&Schuell, 
Dassel,  Germany)  and  blotted  with  specific  antibodies 
as described earlier [43] (Actin, Aurora-A, Aurora-B: all 
from  Sigma,  Munich,  Germany;  S10-HH3:  Millipore, 
Schwalbach, Germany; EGFR: Santa Cruz, Heidelberg, 
Germany;  pEGFR:  Invitrogen,  Darmstadt,  Germany, 
pAKT, pERK: both from New England Biolabs, Frankfurt, 
Germany). 
statistical analysis
Statistical analyses were performed using the 
statistical functions (t-test if not otherwise indicated) of 
GraphPad Prism (GraphPad Software, La Jolla, CA). For 
quantitative variables, means and standard deviations are 
given, for categorical data absolute and relative frequencies. 
The bars shown represent the mean ± standard deviation 
(SD)  or  standard  error  of  the  mean  (SEM).  Spearman 
rank correlation coefficient (r) was correlated to assess 
the relationship between Aurora-A and EGFR expression. 
Also for box plots showing medians, quantiles and ranges 
as well as Kaplan-Meier survival analyses the Statistical 
Package for Social Sciences (SPSS 17.0 Package Facility, 
SPSS  Inc,  IL,  USA)  was  used.  Survival  curves  were 
compared with the log-Rank test. Any p values given are 
two-sided and subject to a local significance level of 0.05.Oncotarget 2011; 2:  599 - 609 608 www.impactjournals.com/oncotarget
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